Topics:
Head and Neck Cancers • Radiation Oncology
How are you using circulating tumor DNA in your clinical decisions for HPV-associated OPSCC?
Answer from: Radiation Oncologist at Academic Institution
We have a post-operative trial where we are using cfDNA as an integral marker to decide on adjuvant therapy for HPV+ OPC.
Sign in or Register to read more